187 related articles for article (PubMed ID: 38448381)
1. Research progress regarding
Jia Q; Ding Q; Shao K; Dang J; Zhang F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 48(12):1874-1881. PubMed ID: 38448381
[TBL] [Abstract][Full Text] [Related]
2. The Role of CYP3A in Health and Disease.
Klyushova LS; Perepechaeva ML; Grishanova AY
Biomedicines; 2022 Oct; 10(11):. PubMed ID: 36359206
[TBL] [Abstract][Full Text] [Related]
3. Significance of the minor cytochrome P450 3A isoforms.
Daly AK
Clin Pharmacokinet; 2006; 45(1):13-31. PubMed ID: 16430309
[TBL] [Abstract][Full Text] [Related]
4. Comparison of steroid hormone hydroxylation mediated by cytochrome P450 3A subfamilies.
Niwa T; Okamoto A; Narita K; Toyota M; Kato K; Kobayashi K; Sasaki S
Arch Biochem Biophys; 2020 Mar; 682():108283. PubMed ID: 32001245
[TBL] [Abstract][Full Text] [Related]
5. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
6. Modification of single-nucleotide polymorphism in a fully humanized CYP3A mouse by genome editing technology.
Abe S; Kobayashi K; Oji A; Sakuma T; Kazuki K; Takehara S; Nakamura K; Okada A; Tsukazaki Y; Senda N; Honma K; Yamamoto T; Ikawa M; Chiba K; Oshimura M; Kazuki Y
Sci Rep; 2017 Nov; 7(1):15189. PubMed ID: 29123154
[TBL] [Abstract][Full Text] [Related]
7. Prediction of progression of chronic atrophic gastritis with Helicobacter pylori and poor prognosis of gastric cancer by CYP3A4.
Zhang F; Wang F; Chen C; Wang T; Hu J; Su R; Li X; Gu B; Tang S; Chen H; Li Y
J Gastroenterol Hepatol; 2020 Mar; 35(3):425-432. PubMed ID: 31441961
[TBL] [Abstract][Full Text] [Related]
8. Stimulatory and Inhibitory Effects of Steroid Hormones and Human Cytochrome P450 (CYP) 3A Inhibitors on Cortisol 6β-Hydroxylation Catalyzed by CYP3A Subfamilies.
Niwa T; Tani M; Suzuki A; Murakami M
Drug Metab Bioanal Lett; 2023; 16(2):73-80. PubMed ID: 37649294
[TBL] [Abstract][Full Text] [Related]
9. [Clinical significance of cytochrome P450 genetic polymorphism--part IV. Cytochrome P450 3A4 and 3A5].
Duricová J; Grundmann M
Ceska Slov Farm; 2011 Dec; 60(6):276-82. PubMed ID: 22312850
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 3A: ontogeny and drug disposition.
de Wildt SN; Kearns GL; Leeder JS; van den Anker JN
Clin Pharmacokinet; 1999 Dec; 37(6):485-505. PubMed ID: 10628899
[TBL] [Abstract][Full Text] [Related]
11. Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43.
Krusekopf S; Roots I; Kleeberg U
Eur J Pharmacol; 2003 Apr; 466(1-2):7-12. PubMed ID: 12679136
[TBL] [Abstract][Full Text] [Related]
12. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450.
Domanski TL; Finta C; Halpert JR; Zaphiropoulos PG
Mol Pharmacol; 2001 Feb; 59(2):386-92. PubMed ID: 11160876
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Stimulatory and Inhibitory Effects of Steroid Hormones and α-Naphthoflavone on Steroid Hormone Hydroxylation Catalyzed by Human Cytochrome P450 3A Subfamilies.
Niwa T; Toyota M; Kawasaki H; Ishii R; Sasaki S
Biol Pharm Bull; 2021; 44(4):579-584. PubMed ID: 33790108
[TBL] [Abstract][Full Text] [Related]
14. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
[TBL] [Abstract][Full Text] [Related]
15. Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43.
Westlind A; Malmebo S; Johansson I; Otter C; Andersson TB; Ingelman-Sundberg M; Oscarson M
Biochem Biophys Res Commun; 2001 Mar; 281(5):1349-55. PubMed ID: 11243885
[TBL] [Abstract][Full Text] [Related]
16. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA.
Koch I; Weil R; Wolbold R; Brockmöller J; Hustert E; Burk O; Nuessler A; Neuhaus P; Eichelbaum M; Zanger U; Wojnowski L
Drug Metab Dispos; 2002 Oct; 30(10):1108-14. PubMed ID: 12228187
[TBL] [Abstract][Full Text] [Related]
17. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
[TBL] [Abstract][Full Text] [Related]
18. Molecular population genetics of human CYP3A locus: signatures of positive selection and implications for evolutionary environmental medicine.
Chen X; Wang H; Zhou G; Zhang X; Dong X; Zhi L; Jin L; He F
Environ Health Perspect; 2009 Oct; 117(10):1541-8. PubMed ID: 20019904
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of human cytochrome P450 enzymes from the CYP3A subfamily in the brains of alcoholic subjects and drug-free controls.
Booth Depaz IM; Toselli F; Wilce PA; Gillam EM
Drug Metab Dispos; 2013 Jun; 41(6):1187-94. PubMed ID: 23491640
[TBL] [Abstract][Full Text] [Related]
20. Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes.
van Waterschoot RA; van Herwaarden AE; Lagas JS; Sparidans RW; Wagenaar E; van der Kruijssen CM; Goldstein JA; Zeldin DC; Beijnen JH; Schinkel AH
Mol Pharmacol; 2008 Mar; 73(3):1029-36. PubMed ID: 18156313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
